|
|
The Body Covers: The 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy
Conference Summaries: Day One
Sunday, September 17, 2000
- Pharmacoeconomics and Epidemiology of Antibiotic Use
- Meet the Experts Session
- Drug-Drug Interactions in HIV Infections
- Potential Role of Protease Inhibitor-Sparing Regimens in Antiretroviral Therapy
- The SENC Trial: Spanish Efavirenz vs Nevirapine Comparison Trial. Preliminary Results of a Prospective, Randomized, Controlled, Open-label Study in HIV+ Naive Individuals (Slide Session 472)
Coverage by Calvin Cohen, M.D.
- Impact of Switching from Protease Inhibitors (PI) to Nevirapine (NVP) or Efavirenz (EFV) in Patients with Viral Suppression (Slide Session 473)
Coverage by Calvin Cohen, M.D.
- The Maintavir Study, Substitution of a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for a Protease Inhibitor (PI) in Patients with Undetectable Plasma HIV-1 Rna: 18 Months Follow-up (Slide Session 474)
Coverage by Calvin Cohen, M.D.
- Successful Substitution of Protease Inhibitors with Sustiva (Efavirenz) in Patients with Undetectable Plasma HIV-1 RNA Levels -- Results of a Prospective, Randomized, Multicenter, Open-label Study (DMP 266-049) (Slide Session 475)
Coverage by Calvin Cohen, M.D.
- Simplified Maintenance Therapy with Abacavir + Lamivudine + Zidovudine in Patients with HAART-Induced Long-Term Suppression of HIV-1 RNA: Final Results (Slide Session 476)
Coverage by Pablo Tebas, M.D.
- A Novel Use of Abacavir to Simplify Therapy & Reduce Toxicity in PI-Experienced Patients Successfully Treated with HAART: 48-Week Results (CNA30017) (Slide Session 477)
Coverage by Pablo Tebas, M.D.
- Temporary Interruption (TI) of SUSTIVA? (Efavirenz, EFV)-Containing Therapy Does Not Impact Virological Response Rates (Slide Session 479)
Coverage by Pablo Tebas, M.D.
- Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Hypersusceptibility (HS) is Common and Improves Short-Term Virologic Response (Slide Session 481)
Coverage by Alvan E. Fisher, M.D.
- Clinical Trials of Antiretroviral Therapy
- Four Drugs are Better than Three Drugs to Maintain Existing HIV Suppression and Reduce Productive Infection (Poster 535)
Coverage by Calvin Cohen, M.D.
- Tolerance, Efficacy and Adherence of Four Regimens of Antiretroviral Therapy (Poster 536)
Coverage by Calvin Cohen, M.D.
- ICC-604: a Pilot Study to Evaluate the Safety, Adherence, Antiviral Activity and Pharmacokinetics (PK) of a Novel Once Daily Regimen of Adefovir Dipivoxil (ADV), Lamivudine (3TC), Didanosine (ddI), and Efavirenz (EFV) in HIV-1 Infected Patients (Pts) (Poster 537)
Coverage by Calvin Cohen, M.D.
- Sustiva (Efavirenz) is Highly Effective and Well Tolerated in Combination with the Nucleosides Stavudine and Lamivudine (Study DMP 266-043) (Poster 538)
Coverage by Calvin Cohen, M.D.
- An Open-label, Randomized, Comparative Study of Stavudine (d4T) + Didanosine (ddI) + Indinavir (IDV) Versus d4T + ddI + Nevirapine (NVP) in Treatment of HIV-Infected Naive Patients (Poster 539)
Coverage by Calvin Cohen, M.D.
- Randomized Salvage Therapy with Saquinavir-Ritonavir (SQV-RTV) versus Saquinavir-Nelfinavir (SQV-NFV) for Highly Experienced HIV-Infected Patients (Poster 543)
Coverage by Calvin Cohen, M.D.
- DIRECT STUDY: A Multi-center, Open-Label, 24-Week Pilot Study with a 24-Week Extension to Evaluate the Safety, Tolerability and Efficacy of Indinavir (IDV)-Ritonavir (RTV) (800/100) BID in Combination with d4T plus 3TC in HIV-Infected Individuals (Poster 544)
Coverage by Edwin DeJesus, M.D.
- Response with Twice Daily (BID) Crixivan plus Norvir Based Regimen (IDV-RTV) in Patients (pts) Failing Protease Inhibitor (PI) Therapy (Poster 545)
Coverage by Edwin DeJesus, M.D.
- Two-Year Follow-Up of ABT-378/Ritonavir (ABT-378/r) in Antiretroviral Naive HIV+ Patients (Poster 546)
Coverage by Mark Holodniy, M.D.
- Time to Treatment Success: 24 weeks is Not Enough in Patients Starting with High Viral Load (VL) in DP-006 (Poster 547)
Coverage by Mark Holodniy, M.D.
- New Anti-HIV Agents
- Pathogenesis of HIV Disease and other Retrovirus Diseases
- Immunology of HIV Infection
|
Advertisement
|
Email
Glossary